Prostate cancer is the most common cancer in men in the U.S., responsible for an estimated 248,530 new cases and 34,130 deaths in 2021. For patients diagnosed with advanced prostate cancer, androgen deprivation therapy (ADT) plays a major role in treatment but may be associated with a broad range of adverse effects. Of these, increased risk of cardiovascular (CV) events is among the most serious, as cardiovascular disease (CVD) is the most common non-cancer cause of death in patients with prosta...

Neuro Oncology Tumor BoardCourse Director:  John Breneman, MDActivity Coordinator:  Cheryl MorganThe location of this series varies.For more information about this series, contact the activity coordinator.

The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients.This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd Amer...

Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies.This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Immunotherapy approaches have revolutionized the treatment of melanoma and ongoing studies are focused on improving outcomes and reducing toxicities with existing and novel therapies. To ensure updated ongoing care for patients, clinicians need to stay abreast with recent clinical trial evidence from different settings of melanoma treatment.This educational Clinical Clip will highlight important advances in immunotherapy approaches for melanoma based on data presented at the 2021 American Societ...